ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.14 USD -2.48% Market Closed
Market Cap: 303.6m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ADC Therapeutics SA

Revenue
119.5m USD
Cost of Revenue
-6.6m USD
Gross Profit
112.9m USD
Operating Expenses
-378.6m USD
Operating Income
-265.7m USD
Other Expenses
-105.3m USD
Net Income
-371m USD

Margins Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
302.9m USD
94%
-222%
-310%
US
Abbvie Inc
NYSE:ABBV
333B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
172.6B USD
63%
20%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.7B USD
86%
41%
-5%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
110.9B USD
87%
31%
32%
US
Gilead Sciences Inc
NASDAQ:GILD
108.9B USD
77%
37%
4%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
145.8B AUD
52%
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD
87%
4%
-3%
KY
Beigene Ltd
SSE:688235
235.8B CNY
84%
-30%
-20%
Country CH
Market Cap 302.9m USD
Gross Margin
94%
Operating Margin
-222%
Net Margin
-310%
Country US
Market Cap 333B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 172.6B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 128.7B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 110.9B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 108.9B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 145.8B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 38B USD
Gross Margin
87%
Operating Margin
4%
Net Margin
-3%
Country KY
Market Cap 235.8B CNY
Gross Margin
84%
Operating Margin
-30%
Net Margin
-20%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
ADC Therapeutics SA
NYSE:ADCT
302.9m USD
529%
-84%
-72%
-285%
US
Abbvie Inc
NYSE:ABBV
333B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
172.6B USD
49%
3%
9%
8%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.7B USD
-3%
-2%
25%
-84%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
110.9B USD
17%
13%
14%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
108.9B USD
5%
2%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
145.8B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38B USD
35%
-2%
4%
9%
KY
Beigene Ltd
SSE:688235
235.8B CNY
-17%
-11%
-23%
-46%
Country CH
Market Cap 302.9m USD
ROE
529%
ROA
-84%
ROCE
-72%
ROIC
-285%
Country US
Market Cap 333B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 172.6B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 128.7B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 110.9B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 108.9B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 145.8B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 38B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%
Country KY
Market Cap 235.8B CNY
ROE
-17%
ROA
-11%
ROCE
-23%
ROIC
-46%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top